EP0267247A1 - Verfahren und reagenz zum nachweis von schädigungen bzw. erkrankungen des herzens - Google Patents
Verfahren und reagenz zum nachweis von schädigungen bzw. erkrankungen des herzensInfo
- Publication number
- EP0267247A1 EP0267247A1 EP87903286A EP87903286A EP0267247A1 EP 0267247 A1 EP0267247 A1 EP 0267247A1 EP 87903286 A EP87903286 A EP 87903286A EP 87903286 A EP87903286 A EP 87903286A EP 0267247 A1 EP0267247 A1 EP 0267247A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- atoms
- hydrogen
- creatine
- sulfonic acid
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/50—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving creatine phosphokinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/70—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving creatine or creatinine
Definitions
- the invention relates to a method and a reagent for the detection of damage or diseases of the heart muscle, such as. B. heart attack, as well as its use for monitoring the course of heart operations, for further observation after a heart attack and for certain indications for cardiac therapy, such as. B. in thrombolytic treatments.
- creatine kinase and that of CK isoenzyme (CK-MB) and that of lactate dehydrogenase (LDH) and glutamate oxaloacetate transaminase (GOT) play a dominant role in clinical practice.
- CK catalyzes the conversion of creatine into creatine phosphate, which is the storage form for high-energy phosphates in this tissue.
- Creatinine is the catabolic end product of mammalian creatine metabolism and is excreted from the blood in the urine via the kidneys.
- creatine kinase in the serum results from an increased enzyme release after damage to the skeletal and cardiac muscles.
- An increase in CK activity can already be observed after 6 - hours after the heart attack, the maximum (10 - 20 times the norm) is reached after about 18 - 24 hours.
- the increase in the activity of the lactate dehydrogenase or of the heart muscle-specific LDH isoenzymes in the serum is likewise based on damaged or destroyed heart muscle tissue. Certain increases are found in 90% of cases 12 hours after the beginning of clinical symptomatology. The maximum LDH increase (2 - 10 times the norm) is between 48 and 72 hours.
- the determination of the GOT activity is also often used as an additional parameter.
- the increase in GOT activity is approximately parallel to that in CK activity.
- a disadvantage of the determination of the enzymes mentioned for the detection of myocardial infarction and other heart muscle damage is, however, that a significant increase in the enzyme activity in the blood or serum occurs only about 8 hours after the onset of the damage, where the maximum is reached after about 24 hours.
- Corresponding electrocardiograms do not provide clear, reliable statements in approximately 15% of the cases.
- the known methods are therefore only of limited suitability for use in the early specific diagnosis of heart attack or other damage to the heart muscle tissue.
- targeted therapy based on a specific diagnosis that starts as early as possible, ie up to about 4 hours after the event, can achieve a therapeutic effect, particularly in the case of an acute heart attack.
- the invention was therefore based on the object of developing a simple, quick, specific method for detecting heart attack and other damage to the heart muscle, which increases the meaningfulness of the heart attack diagnosis.
- At least one low-molecular metabolite for example creatine (molecular weight 131 g-mol " 1 ) or creatine phosphate, in the sample of a body fluid such as urine, blood, serum, plasma, saliva and its ultrafiltrates or of Tissue extracts is determined.
- a body fluid such as urine, blood, serum, plasma, saliva and its ultrafiltrates or of Tissue extracts
- heart damage or disease The most common forms of heart damage or disease are acute heart attack, micronecrosis, acute and dumb myocardial ischemia, and heart contusion after blunt thoracic trauma.
- metabolites is to be understood as meaning the products resulting from the creatine metabolism or the products implemented in this metabolism, as well as possible biological and chemical preliminary and secondary products and artificial artifacts.
- substrates creatine, creatine phosphate, creatinine, sarcosine, phosphoenolpyruvate, pyruvate, lactate, urea, glycine, formaldehyde, amino acids of the heart muscle and their biochemical and chemical conversion products which, due to their low molecular weight, cause damage to the heart muscle tissue can be released more.
- Creatine which is mainly synthesized from glycine and arginine in the liver and kidney and is mainly excreted as creatinine, is only present in low concentrations in serum and urine in healthy humans and mammals (approx. 5 - 10 mg / 1 or 2 - 4 mg / 1).
- creatinine In contrast to the creatinine determination, the determination of creatine has so far been used essentially for clinical-chemical research. For example, an increased creatine content in the blood (creatinemia) is observed with increasing renal insufficiency (see, for example, JP 58.009.699). Furthermore, patients with haemolytic anemia during the painful haemolytic crisis were found to have a 10 to 20-fold increase in the level of creaatin in the 24-hour urine (Beyer et al., Clin. Chem. ⁇ 1, 1232-1234 (1985)). In addition, an increased creatine level in the serum and in the urine is observed in various diseases of the skeletal muscles (Yasuhara et al., Clin. Chim.
- the determination of a low-molecular metabolite to detect an acute heart attack or other damage to the heart muscle or heart diseases is a completely new principle of biochemical cardiac diagnostics.
- the respective metabolite can be determined in the sample of a body fluid either enzymatically via coupled enzyme reactions or via purely chemical reactions, with photometric detection being preferred.
- creatine can be used in a coupled reaction with creatine kinase, pyruvate kinase and lactate dehydrogenase and the measurement of the NAD + that ultimately arises in the UV range (in: HU Bergmeyer, Methods of Enzymatic Analysis, 3th edn.
- creatine using the enzymes creatinase (creatina idinohydrolase, EC3.5.3.3.) And sarcosine oxidase (or sarcosine dehydrogenase) and measurement of H2O2 or used O2 (or formed NADH or used NAD + ) or Formaldehyde possible.
- the determination of the metabolite, z. B. des Crea ⁇ tins, for heart damage such as heart attack, takes place in the period of about 1 to 24 hours, preferably in the period of 2 to 8 hours, with a maximum at about 3 hours after the onset of heart damage.
- the measurement up to 24 hours after the occurrence of the acute heart attack can be used for further medical observation, such as e.g. B. to secure the CK-dependent diagnostics or to detect any re-infarcts that may occur (see Fig. 1 and 2).
- Urine is preferably used as the body fluid for the determination of the creatine, since the increase in the creatine is significantly higher here.
- the enzymatic method is advantageously used for the detection of cardiac damage, with the addition of creatinamidinohydrolase (creatinase) and Sarcosine oxidase (EC1.5.3.1) hydrogen peroxide ultimately formed from creatine with peroxidase and a color-forming reagent for a dye is used.
- Creatinase creatinamidinohydrolase
- Sarcosine oxidase EC1.5.3.1
- sarcosine dehydrogenase can also be used and NADH and / or formaldehyde can be determined.
- the true creatine concentration is then calculated from the difference in the measurement signals.
- HPLC High Performance Liquid Chromatography
- the net content of creatine is obtained by subtracting this blank value from the first measurement.
- the procedure for determining the creatine phosphate is analogous.
- creatine phosphine (and ADP), creatine aminohydrolase and sarcosine oxidase are formed from creatine phosphate H2O2 (which is quantified photometrically in a corresponding subsequent reaction)
- a further determination approach without creatine kinase (and ADP) is connected upstream or in parallel leads.
- H2O2 formed from creatine and sarcosine is detected.
- the net content of creatine phosphate in the sample is determined by forming the difference between the two determination values.
- Another object of the invention is a hydrogen peroxide formed tion for 'the erfindungs ⁇ proper method, especially for the determination of creatine, suitable color-forming reagent for the detection of the sarcosine-reaction.
- Numerous compounds are described in the literature which can be used as indicators for the detection of hydrogen peroxide with peroxidase as catalyst. Such indicators are: benzidine and benzidine derivatives, various phenols, polyphenols, such as. B. guaiac resin, leuco dyes such. B.
- n and m can mean the numbers from 1 to 3,
- X and Y are a valence line, an arylene or hydroxyalkylene radical with 1-6 C atoms, R 1 and R 2 are hydrogen, a hydroxy, alkyl or alkoxy group with 1-6 C atoms, a carboxyl, sulfonic acid , can be an acetamido or a P (O) (OR) (R 1 ) group,
- P represents a phosphorus atom
- R is hydrogen or an alkyl group with 1-6 C atoms and R 1 is a hydroxyl, an aryl, alkyl or alkoxy group mi
- R 3 can be hydrogen, halogen, a carboxyl or a sulfonic acid group
- halogen, iodine, bromine and preferably comprises chlorine and fluorine
- R 4 and R 7 are hydrogen, an alkoxy or alkyl group with 1 to 6 carbon atoms,
- R 5 and R 6 represent hydrogen, an aryl or alkyl group with 1-6 C atoms and
- R 5 and R 7 or R 6 and R 4 in the event that the two substituents are ortho to one another, together can form a saturated or unsaturated hydrocarbon chain with 6 carbon atoms which are substituted by hydroxyl or oxo groups can,
- aniline derivatives are in particular (N-methylanilino) methanephosphonic acid, N-ethyl-N- (2-hydroxy-3-sulfopropyl) -m-toluidine (TOOS), N-ethyl-N-sulfopropylaniline (ALPS), N- Ethyl-N-sulfopropyl-toluidine (TOPS), N-ethyl-N-sulfopropyl-m-anisidine (ADPS), N-ethyl-N-sulfopropyl-3,5-dimethylaniline (MAPS), N-ethyl-N- sulfopropyl-3,5-dimethoxyaniline (DAPS), N-sulfopropyl-3,5-dimethoxyaniline (HDAPS), N-ethyl-N- (2-hydroxy-3-sulfopropyl) aniline (ALOS), N-ethyl-N- (2-hydroxy-3
- HETC 2,3,4-tetrahydroquinoline
- THCMP 1,2,3,4-tetrahydroquinoline-N-methanephosphonic acid
- TBHB 2,4,6-tribromo-3-hydroxybenzoic acid
- 2,4,6-triiodo-3-hydroxybenzoic acid can be used for the process according to the invention.
- Examples of possible electron and radical acceptors are 4-aminophenazone (4-AAP), 3-methyl-2-benzothiazolinone hydrazone (MBTH) and 3-methyl-2-benzothiazolinone hydrazone-6-sulfonic acid (S-MBTH) other substances known for their oxidative coupling ability can also be used in the same way.
- the coupling of 4-aminophenazone (4-AAP) or 3-methyl-2-benzothiazolinone hydrazone-6-sulfonic acid (S-MBTH) with N-ethyl-N- (2-hydroxy-3-sulfopropyl) has been particularly preferred.
- m-toluidine TOOS or (N-methylanilino) methanephosphonic acid or S-MBTH with TBHB
- TOOS m-toluidine
- S-MBTH m-toluidine
- An essential part of the present invention consists in to have recognized that the aniline coupling components, such as TOOS, are surprisingly superior to the phenolic coupling components, such as TBHB, in particular in combination with 4-AAP.
- the reagent according to the invention can be in dissolved or dry form. It can be on a suitable carrier, e.g. B. a film impregnated with sarcosine pre-reaction zone.
- a diagnostic agent in the form of a test strip can be produced by preferably impregnating filter paper, cellulose or synthetic fiber fleece with solutions of the reagents required, which are usually used for the production of test strips, in volatile solvents, such as acetone. This can be done in one or more impregnation steps.
- the finished test papers can be used as such or glued to handles in a manner known per se or preferably sealed between plastics and a fine-mesh network.
- the creating content in serum and urine was determined enzymatically by healthy-looking persons in the manner mentioned in the description section.
- serum creatine values 138 people, divided according to age and gender, were used. Blood was drawn from all individuals after a five-day protein diet. A concentration range of 5.7 - 10.4 mg / 1 creatine in serum was obtained for male and female persons between the ages of 46 and 85 (see Table 1).
- the determination of the urine creating content resulted in a mean value of 2.7 mg / 24 h with a standard deviation of the mean value of 1.2 mg / 24 h.
- FIGS. 1 and 2 show a typical behavior of the CK and CK -MB enzyme activities and of creatine in urine and serum.
- Ep c __ x ⁇ o (mg / dl)
- the determination is linear up to a concentration of 20 mg / 100 ml urine.
- FIGS. 1 and 2 show the results of the creatine determination in the urine or serum in comparison to the activity of the CK or CK-MB i serum of a typical heart attack patient up to 36 hours after the appearance of the symptoms.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Description
Claims
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BE216599 | 1986-04-28 | ||
BE0/216599A BE904688A (nl) | 1986-04-28 | 1986-04-28 | Een nieuw principe om de diagnose te stellen van acuut myocardinfarct bij de mens en bij zoogdieren, alsook van andere beschadigingen van het myocardweefsel door middel van de dosage van creatine in lichaamsvloeistoffen. |
BE0/217095A BE905345A (nl) | 1986-08-29 | 1986-08-29 | Een nieuwe methode om creatinefosfaat (cp) te bepalen in lichaamsvloeistoffen, weefsels en de extracten daarvan bij de mens en de zoogdieren. |
BE217095 | 1986-08-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0267247A1 true EP0267247A1 (de) | 1988-05-18 |
Family
ID=25654909
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP87106028A Withdrawn EP0243901A1 (de) | 1986-04-28 | 1987-04-24 | Verfahren und Reagenz zum Nachweis von Schädigungen bzw. Erkrankungen des Herzens |
EP87903286A Withdrawn EP0267247A1 (de) | 1986-04-28 | 1987-04-24 | Verfahren und reagenz zum nachweis von schädigungen bzw. erkrankungen des herzens |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP87106028A Withdrawn EP0243901A1 (de) | 1986-04-28 | 1987-04-24 | Verfahren und Reagenz zum Nachweis von Schädigungen bzw. Erkrankungen des Herzens |
Country Status (7)
Country | Link |
---|---|
EP (2) | EP0243901A1 (de) |
JP (1) | JPS63503328A (de) |
KR (1) | KR880701291A (de) |
AU (1) | AU7397787A (de) |
DE (1) | DE3790229D2 (de) |
FI (1) | FI875739A0 (de) |
WO (1) | WO1987006619A1 (de) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2008289172B2 (en) * | 2007-08-16 | 2013-01-17 | Metabolon, Inc. | Metabolomic profiling of prostate cancer |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4105499A (en) * | 1976-10-06 | 1978-08-08 | Kiyasu John Y | Heart attack screening method, apparatus and kit for same |
DE3124594A1 (de) * | 1981-06-23 | 1983-01-05 | Boehringer Mannheim Gmbh, 6800 Mannheim | Mittel und verfahren zum nachweis von wasserstoffperoxid |
JPS59183698A (ja) * | 1983-04-02 | 1984-10-18 | Wako Pure Chem Ind Ltd | 基質又は酵素活性の定量方法 |
DE3425219A1 (de) * | 1984-07-09 | 1986-02-06 | Boehringer Mannheim Gmbh, 6800 Mannheim | Verwendung von anilinderivaten als kupplungskomponente in oxidativen farbbildungsreaktionen |
-
1987
- 1987-04-24 EP EP87106028A patent/EP0243901A1/de not_active Withdrawn
- 1987-04-24 DE DE87EP8700223T patent/DE3790229D2/de not_active Expired
- 1987-04-24 KR KR1019870701261A patent/KR880701291A/ko not_active Application Discontinuation
- 1987-04-24 AU AU73977/87A patent/AU7397787A/en not_active Abandoned
- 1987-04-24 JP JP62503032A patent/JPS63503328A/ja active Pending
- 1987-04-24 EP EP87903286A patent/EP0267247A1/de not_active Withdrawn
- 1987-04-24 WO PCT/EP1987/000223 patent/WO1987006619A1/de not_active Application Discontinuation
- 1987-12-28 FI FI875739A patent/FI875739A0/fi not_active Application Discontinuation
Non-Patent Citations (1)
Title |
---|
See references of WO8706619A1 * |
Also Published As
Publication number | Publication date |
---|---|
AU7397787A (en) | 1987-11-24 |
EP0243901A1 (de) | 1987-11-04 |
JPS63503328A (ja) | 1988-12-02 |
FI875739A (fi) | 1987-12-28 |
DE3790229D2 (en) | 1988-08-25 |
WO1987006619A1 (en) | 1987-11-05 |
FI875739A0 (fi) | 1987-12-28 |
KR880701291A (ko) | 1988-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE3012368C2 (de) | Verfahren und diagnostische Mittel zum Nachweis von Redox-Reaktionen | |
DE3021259C2 (de) | Mit Amidopyrin verbessertes Trinder-Reagens und Verfahren zur quantitativen Bestimmung von Wasserstoffperoxid bei der enzymatischen Oxidation von Stoffwechselprodukten mit diesem Reagens | |
DE2847202A1 (de) | Verfahren zur bestimmung von triglyceriden | |
EP0114267B1 (de) | Testsystem und Verfahren zur Bestimmung von NAD(P)H | |
EP0068356B1 (de) | Mittel und Verfahren zum Nachweis von Wasserstoffperoxid oder Peroxidasen | |
DE2122255A1 (de) | Verfahren und Reagens zur spezifischen Bestimmung von Creatinin | |
DD209478A5 (de) | Testsystem und verfahren zur bestimmung von substanzen in fluessigkeiten | |
EP0224813B1 (de) | Mittel zur Bestimmung von Peroxidase-Aktivität mit Stabilisator, Verfahren zur Herstellung und seine Verwendung | |
DE2618419A1 (de) | Heterogenes spezifisches bindungsverfahren zur bestimmung eines liganden in einem fluessigen medium und mittel zu dessen durchfuehrung | |
DE2600526C3 (de) | Verfahren zur quantitativen Bestimmung von mit Sauerstoff unter Oxidaseeinwirkung H↓2↓O↓2↓ bildenden Substanzen und Reagens zu seiner Durchführung | |
DE2927054A1 (de) | Testzusammensetzung zur bestimmung von kreatinin, verfahren zu deren herstellung und testeinrichtungen, welche dieselbe enthalten | |
DE2653537C3 (de) | Verfahren und Mittel zur Bestimmung von Hydroperoxiden | |
DE3125667C2 (de) | Verfahren und Mittel zum Nachweis von Wasserstoffperoxid | |
DE3408062A1 (de) | Verfahren zur bestimmung von ss-hydroxibuttersaeure und eine zusammensetzung zur bestimmung von ss-hydroxibuttersaeure | |
DE2459087C3 (de) | Verfahren und Reagenz zur Bestimmung von Serumtriglyceriden | |
EP0267247A1 (de) | Verfahren und reagenz zum nachweis von schädigungen bzw. erkrankungen des herzens | |
DE4321807C2 (de) | Verfahren zur quantitativen Bestimmung von 1,5-Anhydroglucitol und Testpack | |
DE3732688A1 (de) | Verfahren zur spezifischen bestimmung des serumfructosamingehalts sowie hierfuer geeignetes reagenzgemisch | |
DE69433003T2 (de) | Assayverfahren für biologische Komponenten | |
DE4306278C2 (de) | Verfahren zur quantitativen Analyse von 1,5-Anhydroglucitol | |
DE2855433C2 (de) | Testmittel zum Nachweis von Harnsäure | |
CH646792A5 (de) | Testvorrichtung fuer die bestimmung von harnsaeure. | |
DE19742117B4 (de) | Verfahren zur Messung von Harnstoffstickstoff und Untersuchungssets dafür | |
EP0048347A1 (de) | Verfahren und Reagens zur Bestimmung von Glycerin | |
DE4038306C2 (de) | Verfahren zur hochempfindlichen, quantitativen Analyse von Gallensäuren und Zusammensetzung für die quantitative Analyse |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19871222 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LI LU NL SE |
|
17Q | First examination report despatched |
Effective date: 19910304 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 19910716 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: SIEDEL, JOACHIM Inventor name: DE SCHEERDER, IVAN, K. Inventor name: STAEPELS, JOHNNY Inventor name: DELANGHE, JORIS, R. Inventor name: DE BUYZERE, MARC, L. |